[
  {
    "chapterId": "1",
    "chapterTitle": "Epidemiology"
  },
  {
    "chapterId": "2",
    "chapterTitle": "Diagnostic Tests for Latent TB Infection (LTBI)"
  },
  {
    "chapterId": "3",
    "chapterTitle": "Treatment of Latent TB Infection (LTBI)"
  },
  {
    "chapterId": "4",
    "chapterTitle": "Laboratory Diagnosis of Active Tuberculosis"
  },
  {
    "chapterId": "5",
    "chapterTitle": "Treatment of Current (Active) Disease Therapy"
  },
  {
    "chapterId": "6",
    "chapterTitle": "Pregnancy and TB"
  },
  {
    "chapterId": "7",
    "chapterTitle": "Childhood Tuberculosis"
  },
  {
    "chapterId": "8",
    "chapterTitle": "Tuberculosis and Long-Term Care Facilities"
  },
  {
    "chapterId": "9",
    "chapterTitle": "BCG Vaccination"
  },
  {
    "chapterId": "10",
    "chapterTitle": "TB Infection Control: Hospital Isolation Procedures"
  },
  {
    "chapterId": "11",
    "chapterTitle": "Community Tuberculosis Control"
  },
  {
    "chapterId": "12",
    "chapterTitle": "Alternative Housing Program for Homeless TB Patients in Georgia"
  },
  {
    "chapterId": "13",
    "chapterTitle": "Georgia Department of Public Health (DPH)  Community Guidelines for Respiratory Isolation of  Patients with Active TB in the Community"
  },
  {
    "chapterId": "14",
    "chapterTitle": "References"
  },
  {
    "chapterId": "15",
    "chapterTitle": "Appendix: District TB Coordinators (by District)"
  },
  {
    "chapterId": "16",
    "chapterTitle": "For more information"
  }
]





[
  {
    "subChapterId": 1,
    "chapterId": "1",
    "subChapterTitle": "Epidemiology",
    "url": "1_epidemiology"
  },
  {
    "subChapterId": 2,
    "chapterId": "2",
    "subChapterTitle": "Introduction",
    "url": "2_diagnostic_tests_for_latent_tb_infection_(ltbi)"
  },
  {
    "subChapterId": 3,
    "chapterId": "2",
    "subChapterTitle": "Tuberculin Skin Test (TST)",
    "url": "2_diagnostic_tests_for_latent_tb_infection_(ltbi)__a__tuberculin_skin_test"
  },
  {
    "subChapterId": 4,
    "chapterId": "2",
    "subChapterTitle": "Criteria for a Positive Tuberculin Test, by Risk Group",
    "url": "2_diagnostic_tests_for_latent_tb_infection_(ltbi)__b__criteria_for_a_positive_tuberculin_test_by_risk_group"
  },
  {
    "subChapterId": 5,
    "chapterId": "2",
    "subChapterTitle": "Two-Step Testing and the Booster Reaction",
    "url": "2_diagnostic_tests_for_latent_tb_infection_(ltbi)__c__two_step_testing_and_the_booster_reaction"
  },
  {
    "subChapterId": 6,
    "chapterId": "2",
    "subChapterTitle": "Energy Testing",
    "url": "2_diagnostic_tests_for_latent_tb_infection_(ltbi)__d__anergy_testing"
  },
  {
    "subChapterId": 7,
    "chapterId": "2",
    "subChapterTitle": "Interferon-? Release Assays (IGRAs)",
    "url": "2_diagnostic_tests_for_latent_tb_infection_(ltbi)__e__interferon_y_release_assays_(igras)"
  },
  {
    "subChapterId": 8,
    "chapterId": "2",
    "subChapterTitle": "Targeted Testing and Diagnostic Tests for LTBI",
    "url": "2_diagnostic_tests_for_latent_tb_infection_(ltbi)__f__targeted_testing_and_diagnostic_tests_for_ltbi"
  },
  {
    "subChapterId": 9,
    "chapterId": "2",
    "subChapterTitle": "Medical Evaluation After Testing for LTBI",
    "url": "2_diagnostic_tests_for_latent_tb_infection_(ltbi)__g__medical_evaluation_after_testing_for_ltbi"
  },
  {
    "subChapterId": 10,
    "chapterId": "2",
    "subChapterTitle": "Reporting of Pediatric Positive Tests for L",
    "url": "2_diagnostic_tests_for_latent_tb_infection_(ltbi)__h__reporting_of_pediatric_positive_tests_for_ltbi"
  },
  {
    "subChapterId": 11,
    "chapterId": "3",
    "subChapterTitle": "Introduction",
    "url": "3_treatment_of_latent_tb_infection_(ltbi)"
  },
  {
    "subChapterId": 12,
    "chapterId": "3",
    "subChapterTitle": "Treatment Regimens",
    "url": "3_treatment_of_latent_tb_infection_(ltbi)__a__treatment_regimens"
  },
  {
    "subChapterId": 13,
    "chapterId": "3",
    "subChapterTitle": "Monitoring of Patients on Treatment for LTBI",
    "url": "3_treatment_of_latent_tb_infection_(ltbi)__b__monitoring_of_patients_on_treatment_for_ltbi"
  },
  {
    "subChapterId": 14,
    "chapterId": "3",
    "subChapterTitle": "Contacts of MDR-TB Cases",
    "url": "3_treatment_of_latent_tb_infection_(ltbi)__c__contacts_of_mdr_tb_cases"
  },
  {
    "subChapterId": 15,
    "chapterId": "4",
    "subChapterTitle": "Introduction",
    "url": "4_laboratory_diagnosis_of_active_tuberculosis"
  },
  {
    "subChapterId": 16,
    "chapterId": "4",
    "subChapterTitle": "Considerations",
    "url": "4_laboratory_diagnosis_of_active_tuberculosis__a__considerations"
  },
  {
    "subChapterId": 17,
    "chapterId": "4",
    "subChapterTitle": "Selected Diagnostic Test Characteristics",
    "url": "4_laboratory_diagnosis_of_active_tuberculosis__b__selected_diagnostic_test_characteristics"
  },
  {
    "subChapterId": 18,
    "chapterId": "4",
    "subChapterTitle": "Laboratory Diagnosis of Pulmonary Tuberculosis",
    "url": "4_laboratory_diagnosis_of_active_tuberculosis__c__laboratory_diagnosis_of_pulmonary_tuberculosis"
  },
  {
    "subChapterId": 19,
    "chapterId": "4",
    "subChapterTitle": "Laboratory Diagnosis of Extrapulmonary Tuberculosis",
    "url": "4_laboratory_diagnosis_of_active_tuberculosis__d__laboratory_diagnosis_of_extrapulmary_tuberculosis"
  },
  {
    "subChapterId": 20,
    "chapterId": "4",
    "subChapterTitle": "Rapid Molecular Drug Susceptibility Tests (DST)",
    "url": "4_laboratory_diagnosis_of_active_tuberculosis__e__rapid_molecular_drug_susceptibility_tests_(dst)"
  },
  {
    "subChapterId": 21,
    "chapterId": "5",
    "subChapterTitle": "Introduction",
    "url": "0"
  },
  {
    "subChapterId": 22,
    "chapterId": "5",
    "subChapterTitle": "Considerations",
    "url": "0"
  },
  {
    "subChapterId": 23,
    "chapterId": "5",
    "subChapterTitle": "Standard Therapy for Current (Active) Disease",
    "url": "0"
  },
  {
    "subChapterId": 24,
    "chapterId": "5",
    "subChapterTitle": "Special Clinical Situations",
    "url": "0"
  },
  {
    "subChapterId": 25,
    "chapterId": "5",
    "subChapterTitle": "Drug Resistance",
    "url": "0"
  },
  {
    "subChapterId": 26,
    "chapterId": "5",
    "subChapterTitle": "Monitoring Patients on Therapy for Response and Adverse Events",
    "url": "0"
  },
  {
    "subChapterId": 27,
    "chapterId": "5",
    "subChapterTitle": "TB and HIV",
    "url": "0"
  },
  {
    "subChapterId": 28,
    "chapterId": "5",
    "subChapterTitle": "Antiretroviral Therapy (ART) and Treatment of HIV Seropositive Patients with Active Tuberculosis",
    "url": "0"
  },
  {
    "subChapterId": 29,
    "chapterId": "5",
    "subChapterTitle": "Immune Reconstitution Inflammatory Syndrome (IRIS) Associated with Initiation of Antiretroviral Therapy During the Course of TB Therapy",
    "url": "0"
  },
  {
    "subChapterId": 30,
    "chapterId": "5",
    "subChapterTitle": "Treatment of Extrapulmonary TB (Table 19)",
    "url": "0"
  },
  {
    "subChapterId": 31,
    "chapterId": "5",
    "subChapterTitle": "Adjunctive Use of Corticosteroid Therapy (Table 19)",
    "url": "0"
  },
  {
    "subChapterId": 32,
    "chapterId": "6",
    "subChapterTitle": "Treatment for LTBI and Risk Factors",
    "url": "6_pregnancy_and_tb__a__treatment_for_ltbi_and_risk_factors"
  },
  {
    "subChapterId": 33,
    "chapterId": "6",
    "subChapterTitle": "Treatment of Active TB in Pregnancy",
    "url": "6_pregnancy_and_tb__b__treatment_of_active_tb_in_pregnancy"
  },
  {
    "subChapterId": 34,
    "chapterId": "7",
    "subChapterTitle": "Children Tuberculosis",
    "url": "7_childhood_tuberculosis"
  },
  {
    "subChapterId": 35,
    "chapterId": "7",
    "subChapterTitle": "Management Considerations",
    "url": "7_childhood_tuberculosis__a__management_considerations"
  },
  {
    "subChapterId": 36,
    "chapterId": "8",
    "subChapterTitle": "Tuberculosis and Long-Term Care Facilities",
    "url": "8_tuberculosis_and_long-term_care_facilities"
  },
  {
    "subChapterId": 38,
    "chapterId": "9",
    "subChapterTitle": "BCG Vaccination",
    "url": "9_bcg_vaccination"
  },
  {
    "subChapterId": 39,
    "chapterId": "10",
    "subChapterTitle": "Introduction",
    "url": "10_tb_infection_control_hospital_isolation_procedures"
  },
  {
    "subChapterId": 40,
    "chapterId": "10",
    "subChapterTitle": "Administrative Controls",
    "url": "10_tb_infection_control_hospital_isolation_procedures__a__administrative_controls"
  },
  {
    "subChapterId": 41,
    "chapterId": "10",
    "subChapterTitle": "Surveillance for Health Care Workers",
    "url": "10_tb_infection_control_hospital_isolation_procedures__b__surveillance_for_health_care_workers"
  },
  {
    "subChapterId": 42,
    "chapterId": "10",
    "subChapterTitle": "Environmental Controls",
    "url": "10_tb_infection_control_hospital_isolation_procedures__c__environmental_controls"
  },
  {
    "subChapterId": 43,
    "chapterId": "10",
    "subChapterTitle": "Personal Respiratory Protection",
    "url": "10_tb_infection_control_hospital_isolation_procedures__d__personal_respiratory_protection"
  },
  {
    "subChapterId": 44,
    "chapterId": "11",
    "subChapterTitle": "TB Surveillance in Georgia",
    "url": "11_community_tuberculosis_control__a__tb_surveillance_in_georgia"
  },
  {
    "subChapterId": 45,
    "chapterId": "11",
    "subChapterTitle": "TB Case Definitions for Public Health Surveillance",
    "url": "11_community_tuberculosis_control__b__tb_case_definitions_for_public_health_surveillance"
  },
  {
    "subChapterId": 46,
    "chapterId": "11",
    "subChapterTitle": "Role of the Health Department",
    "url": "11_community_tuberculosis_control__c__role_of_the_health_department"
  },
  {
    "subChapterId": 47,
    "chapterId": "11",
    "subChapterTitle": "Hospital Discharge Planning for Patients with Suspected or Proven TB",
    "url": "11_community_tuberculosis_control__d__hospital_discharge_planning_for_patients_with_suspected_or_proven_tb"
  },
  {
    "subChapterId": 48,
    "chapterId": "11",
    "subChapterTitle": "The U.S.-Mexico Binational Tuberculosis Referral Program (CureTB)",
    "url": "11_community_tuberculosis_control__e__the_us-mexico_binational_tuberculosis_referral_program_(curetb)"
  },
  {
    "subChapterId": 49,
    "chapterId": "12",
    "subChapterTitle": "Alternative Housing Program for Homeless TB Patients in Georgia",
    "url": "12_alternative_housing_program_for_homeless_tb_patients_in_georgia"
  },
  {
    "subChapterId": 50,
    "chapterId": "13",
    "subChapterTitle": "Georgia Department of Public Health (DPH) Community Guidelines for Respiratory Isolation of Patients With Active TB in the Community",
    "url": "13_georgia_department_of_public_health_(dph)_community_guidelines_for_respiratory_isolation_of_patients_with_active_tb_in_the_community"
  },
  {
    "subChapterId": 51,
    "chapterId": "14",
    "subChapterTitle": "References",
    "url": "14_references"
  },
  {
    "subChapterId": 52,
    "chapterId": "15",
    "subChapterTitle": "Appendix: District TB Coordinators (by district)",
    "url": "15_appendix_district_tb_coordinators_(by_district)"
  },
  {
    "subChapterId": 53,
    "chapterId": "16",
    "subChapterTitle": "For more information",
    "url": "16_for_more_information"
  }
]




[
  {
    "id": "table_1_interpretation_criteria_for_the_quantiferon_tb_gold_plus_test",
    "subChapterTitle": "Interferon-y Release Assays (IGRAs)",
    "chartTitle": "Interpretation Criteria for the QuantiFERON-TB Gold Plus Test (QFT-Plus)"
  },
  {
    "id": "table_2_interpretation_criteria_for_the_t_spot_tb_test",
    "subChapterTitle": "Interferon-y Release Assays (IGRAs)",
    "chartTitle": "Interpretation Criteria for the T-SPOT.TB Test (TSpot)"
  },
  {
    "id": "table_3_high_prevalence_and_high_risk_groups",
    "subChapterTitle": "Targeted Testing and Diagnostic Tests for LTBI",
    "chartTitle": "High Prevalence and High-Risk Groups"
  },
  {
    "id": "table_4_recommendations_for_regimens_to_treat_latent_tuberculosis_infection",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "Recommendations for regimens to treat latent tuberculosis infection"
  },
  {
    "id": "table_5_dosages_for_recommended_lbti_treatment_regimens",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "Dosages for recommended LBTI treatment regimens "
  },
  {
    "id": "table_6_ltbi_treatment_drug_adverse_reactions",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "LTBI Treatment Drug Adverse Reactions"
  },
  {
    "id": "5_treatment_of_current_(active)_disease_therapy__table7",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "Recommended Regimens for Treatment of Adults and Children with Drug-Susceptible TB Pulmonary TB"
  },
  {
    "id": "5_treatment_of_current_(active)_disease_therapy__table8",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "First-Line TB Drugs: Dosing for Adults (ages 16 and over) Directly ObservedTherapy (DOT) is mandatory"
  },
  {
    "id": "5_treatment_of_current_(active)_disease_therapy__table9",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "Need clinical confirmation of table"
  },
  {
    "id": "5_treatment_of_current_(active)_disease_therapy__table10",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "Need clinical confirmation of table\nDose for either daily or twice weekly therapy"
  },
  {
    "id": "5_treatment_of_current_(active)_disease_therapy__table11",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "LTBI Treatment Drug Adverse Reactions"
  },
  {
    "id": "5_treatment_of_current_(active)_disease_therapy__table12",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "LTBI Treatment Drug Adverse Reactions"
  },
  {
    "id": "5_treatment_of_current_(active)_disease_therapy__table13",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "LTBI Treatment Drug Adverse Reactions"
  },
  {
    "id": "5_treatment_of_current_(active)_disease_therapy__table14",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "LTBI Treatment Drug Adverse Reactions"
  },
  {
    "id": "5_treatment_of_current_(active)_disease_therapy__table15",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "LTBI Treatment Drug Adverse Reactions"
  },
  {
    "id": "5_treatment_of_current_(active)_disease_therapy__table16",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "HHS Panel Recommendations on treatment of Tuberculosis Disease with HIV co-infection: Timing of Antiretroviral Therapy (ART) Initiation relative to TB treatment"
  },
  {
    "id": "5_treatment_of_current_(active)_disease_therapy__table17",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "LTBI Treatment Drug Adverse Reactions"
  },
  {
    "id": "5_treatment_of_current_(active)_disease_therapy__table18",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "LTBI Treatment Drug Adverse Reactions"
  },
  {
    "id": "5_treatment_of_current_(active)_disease_therapy__table19",
    "subChapterTitle": "Treatment Regimens",
    "chartTitle": "LTBI Treatment Drug Adverse Reactions"
  }
]